16.73

2.14% 0.35

Moonlake Immunotherapeutics (MLTX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché MLTX Giù? Forum Previsione

Precedente Chiudi:

$16.38

Aprire:

$16.43

Volume 24 ore:

852.46K

Relative Volume:

0.76

Capitalizzazione di mercato:

$1.22B

Reddito:

Utile/perdita netta:

$-230.32M

Rapporto P/E:

-4.7449

EPS:

-3.5259

Flusso di cassa netto:

$-196.04M

1 W Prestazione:

-2.62%

1M Prestazione:

+1.27%

6M Prestazione:

+65.64%

1 anno Prestazione:

-59.63%

Intervallo 1D:

$16.06

$16.85

Intervallo di 1 settimana:

$16.01

$17.63

Portata 52W:

$5.95

$62.75

Moonlake Immunotherapeutics Stock (MLTX) Company Profile

Nome

Moonlake Immunotherapeutics

Settore

Healthcare (1113)

Industria

Biotechnology (622)

Telefono

41 41 510 8022

Indirizzo

DORFSTRASSE 29, ZUG

Dipendente

130

Cinguettio

Prossima data di guadagno

2026-05-11

Ultimi documenti SEC

MLTX's Discussions on Twitter

Compare MLTX vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
MLTX Moonlake Immunotherapeutics	16.73	1.22B	0	-230.32M	-196.04M	-3.5259
VRTX Vertex Pharmaceuticals Inc	423.92	107.83B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	701.42	73.54B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	783.50	48.72B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	296.11	39.51B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	293.86	32.66B	5.36B	287.73M	924.18M	2.5229

Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-03-23	Aggiornamento	Wolfe Research	Underperform → Outperform
2026-03-19	Aggiornamento	Rothschild & Co Redburn	Neutral → Buy
2026-01-15	Downgrade	Goldman	Neutral → Sell
2026-01-09	Aggiornamento	BTIG Research	Neutral → Buy
2025-11-03	Aggiornamento	H.C. Wainwright	Neutral → Buy
2025-10-02	Downgrade	H.C. Wainwright	Buy → Neutral
2025-10-01	Downgrade	Goldman	Buy → Neutral
2025-09-30	Downgrade	Citigroup	Buy → Neutral
2025-09-30	Downgrade	Wolfe Research	Outperform → Underperform
2025-09-29	Downgrade	BTIG Research	Buy → Neutral
2025-09-29	Downgrade	Jefferies	Buy → Hold
2025-09-29	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2025-09-29	Downgrade	Stifel	Buy → Hold
2025-07-28	Iniziato	Rothschild & Co Redburn	Neutral
2025-05-19	Aggiornamento	Wolfe Research	Peer Perform → Outperform
2025-03-18	Iniziato	RBC Capital Mkts	Outperform
2025-01-17	Aggiornamento	Goldman	Neutral → Buy
2024-11-05	Ripresa	Wedbush	Outperform
2024-08-26	Downgrade	Wolfe Research	Outperform → Peer Perform
2024-06-25	Iniziato	Oppenheimer	Outperform
2024-04-02	Iniziato	Goldman	Neutral
2024-02-15	Iniziato	Wolfe Research	Outperform
2023-12-08	Iniziato	Citigroup	Buy
2023-11-02	Iniziato	Stifel	Buy
2023-09-14	Downgrade	Bryan Garnier	Buy → Neutral
2023-08-31	Iniziato	Needham	Buy
2023-06-15	Iniziato	Barclays	Equal Weight
2023-05-01	Iniziato	Guggenheim	Buy
2023-03-22	Iniziato	Wedbush	Outperform
2023-03-09	Iniziato	BTIG Research	Buy
2023-02-14	Iniziato	Cantor Fitzgerald	Overweight
2023-02-02	Iniziato	Bryan Garnier	Buy
2022-11-11	Iniziato	Jefferies	Buy
2022-08-25	Iniziato	SVB Leerink	Outperform
2022-07-21	Iniziato	H.C. Wainwright	Buy
2022-07-07	Iniziato	Cowen	Outperform

Mostra tutto

Moonlake Immunotherapeutics Borsa (MLTX) Ultime notizie

02:45 AM

MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat

02:45 AM

May 01, 2026

Short Interest in MoonLake Immunotherapeutics (NASDAQ:MLTX) Decreases By 14.2% - MarketBeat

May 01, 2026

Apr 30, 2026

MLTX Price Today: MoonLake Immunotherapeutics Stock Price, Quote & Chart | MEXC - MEXC Exchange

Apr 30, 2026

Apr 29, 2026

MLTX stock garners retail attention on buyout speculation, positive skin condition trial data - MSN

Apr 28, 2026

MLTX Stock Chart | MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ:MLTX) - ChartMill

Apr 28, 2026

Apr 27, 2026

Moonlake surges as no additional studies are required for lead drug - MSN

Apr 27, 2026